Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + rituximab + bendamustine
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
**epcoritamab + rituximab + bendamustine** is a combination regimen under investigation for the treatment of follicular lymphoma and other B-cell non-Hodgkin lymphomas. Epcoritamab is a subcutaneously administered, bispecific monoclonal antibody that engages CD3 on T cells and CD20 on B cells, promoting T cell-mediated cytotoxicity against malignant B cells. Rituximab is a monoclonal antibody targeting CD20, leading to B cell depletion via immune-mediated mechanisms. Bendamustine is an alkylating agent causing DNA damage and apoptosis in rapidly dividing cells. Together, these agents provide both targeted immunotherapy and cytotoxic chemotherapy, aiming to maximize anti-tumor efficacy.
- Other names
- epcoritamab + rituximab + bendamustine
02
Targets
Beyond the preview
Go deeper on epcoritamab + rituximab + bendamustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + rituximab + bendamustine.